BMD188, a novel hydroxamic acid compound, demonstrates potent anti- prostate cancer effects in vitro and in vivo by inducing apoptosis: Requirements for mitochondria, reactive oxygen species, and proteases

Dean G. Tang, Li Li, Zhenyu Zhu, Bindu Joshi, Carl R. Johnson, Lawrence J. Marnett, Kenneth V. Honn, John D. Crissman, Stanislaw Krajewski, John C. Reed, J. Tímár, Arthur T. Porter

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

A newly synthesized cyclic hydroxamic acid compound, BMD188 [cis-1- hydroxy-4-(1-naphthyl)-6-octylpiperidine-2-one], was found to induce the apoptotic death of cultured prostate cancer cells by activating caspase-3. Orally administered BMD188 significantly inhibited the primary growth of prostate cancer cells (Du145) orthotopically implanted into SCID mice. Mechanistic studies indicated that BMD188 did not alter the protein levels of several Bcl-2 family members. In contrast, the BMD188 effect required three essential factors: reactive oxygen species (ROS), the mitochondrial respiratory chain function, and proteases. First, the apoptosis-inducing effect of BMD188 could be blocked by ROS scavengers such as Desferal. Second, both BMD188-induced PARP cleavage as well as PC3 cell apoptosis could be dramatically inhibited by several complex-specific mitochondrial respiration blockers. The involvement of mitochondria was also supported by the observations that BMD188 dramatically altered the mitochondrial distribution and morphology without affecting the cellular ATP levels. Finally, the apoptosis-inducing effect of BMD188 in PC3 cells could be significantly inhibited by serine protease inhibitors (TPCK and TLCK) as well as by caspase inhibitors (zVAD-fmk and DEVD-CHO). Collectively, the present study suggests that BMD188 and its analogs may find clinical applications in the treatment of prostate cancer patients by inducing apoptotic death of prostate cancer cells.

Original languageEnglish
Pages (from-to)179-190
Number of pages12
JournalPathology and Oncology Research
Volume4
Issue number3
Publication statusPublished - 1998

Fingerprint

Hydroxamic Acids
Reactive Oxygen Species
Prostatic Neoplasms
Mitochondria
Peptide Hydrolases
Apoptosis
Tosyllysine Chloromethyl Ketone
Tosylphenylalanyl Chloromethyl Ketone
1-hydroxy-4-(1-naphthyl)-6-octylpiperidine-2-one
In Vitro Techniques
Serine Proteinase Inhibitors
Deferoxamine
Caspase Inhibitors
SCID Mice
Electron Transport
Caspase 3
Respiration
Adenosine Triphosphate

Keywords

  • Apoptosis
  • Chemotherapy
  • Free radical
  • Hydroxamic acid
  • Mitochondria
  • Prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

BMD188, a novel hydroxamic acid compound, demonstrates potent anti- prostate cancer effects in vitro and in vivo by inducing apoptosis : Requirements for mitochondria, reactive oxygen species, and proteases. / Tang, Dean G.; Li, Li; Zhu, Zhenyu; Joshi, Bindu; Johnson, Carl R.; Marnett, Lawrence J.; Honn, Kenneth V.; Crissman, John D.; Krajewski, Stanislaw; Reed, John C.; Tímár, J.; Porter, Arthur T.

In: Pathology and Oncology Research, Vol. 4, No. 3, 1998, p. 179-190.

Research output: Contribution to journalArticle

Tang, Dean G. ; Li, Li ; Zhu, Zhenyu ; Joshi, Bindu ; Johnson, Carl R. ; Marnett, Lawrence J. ; Honn, Kenneth V. ; Crissman, John D. ; Krajewski, Stanislaw ; Reed, John C. ; Tímár, J. ; Porter, Arthur T. / BMD188, a novel hydroxamic acid compound, demonstrates potent anti- prostate cancer effects in vitro and in vivo by inducing apoptosis : Requirements for mitochondria, reactive oxygen species, and proteases. In: Pathology and Oncology Research. 1998 ; Vol. 4, No. 3. pp. 179-190.
@article{97835191e5144a9ca210524fdb06c88f,
title = "BMD188, a novel hydroxamic acid compound, demonstrates potent anti- prostate cancer effects in vitro and in vivo by inducing apoptosis: Requirements for mitochondria, reactive oxygen species, and proteases",
abstract = "A newly synthesized cyclic hydroxamic acid compound, BMD188 [cis-1- hydroxy-4-(1-naphthyl)-6-octylpiperidine-2-one], was found to induce the apoptotic death of cultured prostate cancer cells by activating caspase-3. Orally administered BMD188 significantly inhibited the primary growth of prostate cancer cells (Du145) orthotopically implanted into SCID mice. Mechanistic studies indicated that BMD188 did not alter the protein levels of several Bcl-2 family members. In contrast, the BMD188 effect required three essential factors: reactive oxygen species (ROS), the mitochondrial respiratory chain function, and proteases. First, the apoptosis-inducing effect of BMD188 could be blocked by ROS scavengers such as Desferal. Second, both BMD188-induced PARP cleavage as well as PC3 cell apoptosis could be dramatically inhibited by several complex-specific mitochondrial respiration blockers. The involvement of mitochondria was also supported by the observations that BMD188 dramatically altered the mitochondrial distribution and morphology without affecting the cellular ATP levels. Finally, the apoptosis-inducing effect of BMD188 in PC3 cells could be significantly inhibited by serine protease inhibitors (TPCK and TLCK) as well as by caspase inhibitors (zVAD-fmk and DEVD-CHO). Collectively, the present study suggests that BMD188 and its analogs may find clinical applications in the treatment of prostate cancer patients by inducing apoptotic death of prostate cancer cells.",
keywords = "Apoptosis, Chemotherapy, Free radical, Hydroxamic acid, Mitochondria, Prostate cancer",
author = "Tang, {Dean G.} and Li Li and Zhenyu Zhu and Bindu Joshi and Johnson, {Carl R.} and Marnett, {Lawrence J.} and Honn, {Kenneth V.} and Crissman, {John D.} and Stanislaw Krajewski and Reed, {John C.} and J. T{\'i}m{\'a}r and Porter, {Arthur T.}",
year = "1998",
language = "English",
volume = "4",
pages = "179--190",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - BMD188, a novel hydroxamic acid compound, demonstrates potent anti- prostate cancer effects in vitro and in vivo by inducing apoptosis

T2 - Requirements for mitochondria, reactive oxygen species, and proteases

AU - Tang, Dean G.

AU - Li, Li

AU - Zhu, Zhenyu

AU - Joshi, Bindu

AU - Johnson, Carl R.

AU - Marnett, Lawrence J.

AU - Honn, Kenneth V.

AU - Crissman, John D.

AU - Krajewski, Stanislaw

AU - Reed, John C.

AU - Tímár, J.

AU - Porter, Arthur T.

PY - 1998

Y1 - 1998

N2 - A newly synthesized cyclic hydroxamic acid compound, BMD188 [cis-1- hydroxy-4-(1-naphthyl)-6-octylpiperidine-2-one], was found to induce the apoptotic death of cultured prostate cancer cells by activating caspase-3. Orally administered BMD188 significantly inhibited the primary growth of prostate cancer cells (Du145) orthotopically implanted into SCID mice. Mechanistic studies indicated that BMD188 did not alter the protein levels of several Bcl-2 family members. In contrast, the BMD188 effect required three essential factors: reactive oxygen species (ROS), the mitochondrial respiratory chain function, and proteases. First, the apoptosis-inducing effect of BMD188 could be blocked by ROS scavengers such as Desferal. Second, both BMD188-induced PARP cleavage as well as PC3 cell apoptosis could be dramatically inhibited by several complex-specific mitochondrial respiration blockers. The involvement of mitochondria was also supported by the observations that BMD188 dramatically altered the mitochondrial distribution and morphology without affecting the cellular ATP levels. Finally, the apoptosis-inducing effect of BMD188 in PC3 cells could be significantly inhibited by serine protease inhibitors (TPCK and TLCK) as well as by caspase inhibitors (zVAD-fmk and DEVD-CHO). Collectively, the present study suggests that BMD188 and its analogs may find clinical applications in the treatment of prostate cancer patients by inducing apoptotic death of prostate cancer cells.

AB - A newly synthesized cyclic hydroxamic acid compound, BMD188 [cis-1- hydroxy-4-(1-naphthyl)-6-octylpiperidine-2-one], was found to induce the apoptotic death of cultured prostate cancer cells by activating caspase-3. Orally administered BMD188 significantly inhibited the primary growth of prostate cancer cells (Du145) orthotopically implanted into SCID mice. Mechanistic studies indicated that BMD188 did not alter the protein levels of several Bcl-2 family members. In contrast, the BMD188 effect required three essential factors: reactive oxygen species (ROS), the mitochondrial respiratory chain function, and proteases. First, the apoptosis-inducing effect of BMD188 could be blocked by ROS scavengers such as Desferal. Second, both BMD188-induced PARP cleavage as well as PC3 cell apoptosis could be dramatically inhibited by several complex-specific mitochondrial respiration blockers. The involvement of mitochondria was also supported by the observations that BMD188 dramatically altered the mitochondrial distribution and morphology without affecting the cellular ATP levels. Finally, the apoptosis-inducing effect of BMD188 in PC3 cells could be significantly inhibited by serine protease inhibitors (TPCK and TLCK) as well as by caspase inhibitors (zVAD-fmk and DEVD-CHO). Collectively, the present study suggests that BMD188 and its analogs may find clinical applications in the treatment of prostate cancer patients by inducing apoptotic death of prostate cancer cells.

KW - Apoptosis

KW - Chemotherapy

KW - Free radical

KW - Hydroxamic acid

KW - Mitochondria

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=17344366112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17344366112&partnerID=8YFLogxK

M3 - Article

C2 - 9761936

AN - SCOPUS:17344366112

VL - 4

SP - 179

EP - 190

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 3

ER -